Therapeutic Outlook in DLBCL: Evaluating Treatment Sequencing from Front-line to Relapsed Refractory Disease - Episode 3

The Evolving First-line Treatment Approach for DLBCL

, , , , ,

An exploration of how first-line treatment practices for DLBCL have evolved with new options, emphasizing the role of relapsed/refractory disease risk in guiding treatment selection.

EP. 1: Emerging Updates in Front-line Treatment Approach of DLBCL
EP. 2: Insights from POLARIX: How do Novel Perspectives Influence Treatment Outcomes in DLBCL?
Now Viewing
EP. 3: The Evolving First-line Treatment Approach for DLBCL
EP. 4: Future Considerations for Front-line Treatment of DLBCL
EP. 5: Role of Testing in Treatment Decisions - ClonoSeq, PhaseSeq, MRD+Disease

Video content above is prompted by the following:

  • In recent years, how has your practice changed with new 1L treatment options available?
  • What role does the potential for relapsed/refractory (RR) disease play in 1L treatment selections?